Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Home
- Home
About BR&R
Biosimilar Approval Status
BR&R Product Profiles
- Abrilada
- Amjevita
- Avasola
- Byooviz
- Cyltezo
- Erelzi
- Eticovo
- Fulphila
- Fylnetra
- Hadlima
- Herzuma
- Hulio
- Hyrimoz
- Inflectra
- Kanjinti
- Mvasi
- Nivestym
- Nyvepria
- Ogivri
- Ontruzant
- Releuko
- Renflexis
- Retacrit
- Rezvoglar
- Riabni
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Yusimry
- Zarxio
- Ziextenzo
- Zirabev
Contact Us
The 2023 Biosimilars Market Report

$0.00 0 items

pfenex-254_(2)[1]

Stanton Mehr July 17, 2017

Published by Stanton Mehr

View all posts by Stanton Mehr

Published July 17, 2017

Post navigation

Previous Post pfenex-254_(2)[1]

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

SM Health Comm

Search for:

Recent Posts

Celltrion’s Adalimumab Biosimilar Yuflyma® Receives FDA Approval May 25, 2023
Amgen Settles With J&J: Its Ustekinumab Biosimilar to Launch by Jan 1, 2025 May 24, 2023
Why Aren’t There More Patent Cases Pending, Considering the Size of the Biosimilar Pipeline? May 15, 2023
A Conversation with Thomas Nusbickel, Chief Commercial Officer, Senior VP, Celltrion USA May 11, 2023
Prospective Biosimilar Maker Lannett Files Chapter 11 Bankruptcy May 4, 2023
First-Quarter Sales of Adalimumab Reveal Plenty of Savings, but Little Early Revenue for Amgen April 28, 2023
A Conversation With Sarfaraz K. Niazi, PhD: Part 2 April 17, 2023
The Drug Industry Rightly Fears Judicial Overreach April 13, 2023
A Conversation With Sarfaraz K. Niazi, PhD: Part 1 April 11, 2023
Biosimilar Bytes April 6, 2023

Recent Comments

	Celltrion's Pen… on The Implications of Celltrion’…
	40th Biosimilar Appr… on FDA Approves Fresenius Kabi’s…
	Biogen Announces Sub… on Tocilizumab Biosimilars Approa…
	J&J Slaps Patent… on Ustekinumab Biosimilars Update
	J&J Slaps Patent… on Preliminary Phase 3 Study Data…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Top Posts & Pages

Biosimilar Approval Status
Zarxio
Momenta Drops Out of Biosimilar Adalimumab Competition
Amgen/Allergan Partners Announce Launches of Herceptin and Avastin Biosimilars
An Eventful May Upcoming for Biosimilars
Why Aren't There More Patent Cases Pending, Considering the Size of the Biosimilar Pipeline?
Herzuma
Coherus’ Struggling Picture Prior to Udenyca On-Body Injector Approval and Yusimry Launch
Tocilizumab Biosimilars Approaching: Developments on Three Fronts
Momenta Signs Licensing Deal With Abbvie. Did It Have a Choice?

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

Twitter
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions

Copyright

Copyright 2013-2023 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.